Cure of short- and long-term experimental Chagas' disease using D0870

Science

Volumn 273, Issue 5277, 1996, Pages 969-971

  Urbina, Julio A ^a   Payares, Gilberto ^b   Molina, Judith ^b   Sanoja, Cristina ^b   Liendo, Andreína ^a   Lazardi, Keyla ^a   Piras, Marta M ^c   Piras, Romano ^c   Perez, Norma ^a   Wincker, Patrick ^d   Ryley, John F ^e  

^a INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

^b UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^c Centro Medico Docente La Trinidad   (Venezuela)

^d UNIV MONTPELLIER   (France)

^e NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DIFLUOROPHENYL) 1 [3 [2 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL]VINYL] 1,2,4 TRIAZOL 1 YL] 3 (1,2,4 TRIAZOL 1 YL) 2 PROPANOL; KETOCONAZOLE; NIFURTIMOX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG MECHANISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRYPANOSOMA CRUZI;

ANIMALIA; PROTOZOA; TRYPANOSOMA; TRYPANOSOMA CRUZI;

EID: 9444291409     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.273.5277.969     Document Type: Article

References (34)

1. World Bank, World Development Report 1993: Investing in Health (Oxford Univ. Press, Oxford, 1993).
2. A. Rassi and A. O. Luquetti. in Chagas' Disease (American Trypanosomiasis): Its Impact on Transfusion and Clinical Medicine, S. Wendel, Z. Brener, M. E. Camargo, A. Rassi, Eds. (ISBT BRAZIL'92, São Paulo, Brazil, 1992), p. 237.
3. S. L. de Castro. Acta Trop. 53, 83 (1993).
4. H. Vanden Bossche, in Modern Selective Fungicides: Properties, Applications, Mechanism of Action, H Lyr, Ed. (Gustav Fisher Verlag, Jena, Germany, 1995), p. 431; Vanden Bossche and P. Marichal, in Recent Progress in Antifungal Chemotherapy, H. Yamaguchi, G. S. Kobayashi, H. Takahashi, Eds. (Marcel Dekker, New York, 1992), p. 25.
5. H. Vanden Bossche, in Modern Selective Fungicides: Properties, Applications, Mechanism of Action, H Lyr, Ed. (Gustav Fisher Verlag, Jena, Germany, 1995), p. 431; Vanden Bossche and P. Marichal, in Recent Progress in Antifungal Chemotherapy, H. Yamaguchi, G. S. Kobayashi, H. Takahashi, Eds. (Marcel Dekker, New York, 1992), p. 25.
6. J. A. Urbina, K. Lazardi, T. Aguirre, M. M. Piras, R. Piras, Antimicrob. Agents Chemother. 32, 1237 (1988).
7. J. A. Urbina et al., ibid. 37, 580 (1993).
8. R. A. Maidonado, J. Molina, G. Payares, J. A. Urbina, ibid., p. 1353.
9. J. A. Urbina, J. Vivas, G. Visbal, L. M. Contreras, Mol. Biochem. Parasitol. 73, 199 (1995).
10. J. A. Urbina et al., Chemotherapy 42, 294 (1996).
11. R. E. McCabe, J. Infect. Dis. 158, 1408 (1988); A. A. B. Moreira et al., Rev. Inst. Med. Trop. Sao Paulo 34, 177 (1992); Z. Brener et al., Mem. Inst. Oswaldo Cruz Rio J. 88, 149 (1993).
12. R. E. McCabe, J. Infect. Dis. 158, 1408 (1988); A. A. B. Moreira et al., Rev. Inst. Med. Trop. Sao Paulo 34, 177 (1992); Z. Brener et al., Mem. Inst. Oswaldo Cruz Rio J. 88, 149 (1993).
13. R. E. McCabe, J. Infect. Dis. 158, 1408 (1988); A. A. B. Moreira et al., Rev. Inst. Med. Trop. Sao Paulo 34, 177 (1992); Z. Brener et al., Mem. Inst. Oswaldo Cruz Rio J. 88, 149 (1993).
14. J. F. Ryley, S. McGregor, R. G. Wilson, Ann. N.Y. Acad. Sci. 544, 310 (1988).
15. J. A. Urbina, K. Lazardi, T. Aguirre, M. M. Piras, R. Piras, Antimicrob. Agents Chemother. 35, 730 (1991); K. Lazardi, J. A. Urbina, W. DeSouza, ibid., p. 736.
16. J. A. Urbina, K. Lazardi, T. Aguirre, M. M. Piras, R. Piras, Antimicrob. Agents Chemother. 35, 730 (1991); K. Lazardi, J. A. Urbina, W. DeSouza, ibid., p. 736.
17. H. Yamada et al., ibid. 37, 2412 (1993).
18. K. V. Clemons, L. H. Hanson, D. A. Stevens, ibid., p. 1177; K. V. Clemons and D. A. Stevens, J. Med. Vet. Mycol. 32, 323 (1994); B. A. Atkinson, R. Bocanegra, A. L. Colombo, J. R. Graybill, Antimicrob. Agents Chemother. 38, 1604 (1994); K. V. Clemons and D. A. Stevens, ibid. 39, 778 (1995); N. C. Karyotakis, M. C. Dignani, R. Hachem, E. J. Anaissie, ibid., p. 571; H. M. Wardle, D. Law, C. B. Moore, C. Mascn, D. W. Denning, ibid., p. 868.
19. K. V. Clemons, L. H. Hanson, D. A. Stevens, ibid., p. 1177; K. V. Clemons and D. A. Stevens, J. Med. Vet. Mycol. 32, 323 (1994); B. A. Atkinson, R. Bocanegra, A. L. Colombo, J. R. Graybill, Antimicrob. Agents Chemother. 38, 1604 (1994); K. V. Clemons and D. A. Stevens, ibid. 39, 778 (1995); N. C. Karyotakis, M. C. Dignani, R. Hachem, E. J. Anaissie, ibid., p. 571; H. M. Wardle, D. Law, C. B. Moore, C. Mascn, D. W. Denning, ibid., p. 868.
20. K. V. Clemons, L. H. Hanson, D. A. Stevens, ibid., p. 1177; K. V. Clemons and D. A. Stevens, J. Med. Vet. Mycol. 32, 323 (1994); B. A. Atkinson, R. Bocanegra, A. L. Colombo, J. R. Graybill, Antimicrob. Agents Chemother. 38, 1604 (1994); K. V. Clemons and D. A. Stevens, ibid. 39, 778 (1995); N. C. Karyotakis, M. C. Dignani, R. Hachem, E. J. Anaissie, ibid., p. 571; H. M. Wardle, D. Law, C. B. Moore, C. Mascn, D. W. Denning, ibid., p. 868.
21. K. V. Clemons, L. H. Hanson, D. A. Stevens, ibid., p. 1177; K. V. Clemons and D. A. Stevens, J. Med. Vet. Mycol. 32, 323 (1994); B. A. Atkinson, R. Bocanegra, A. L. Colombo, J. R. Graybill, Antimicrob. Agents Chemother. 38, 1604 (1994); K. V. Clemons and D. A. Stevens, ibid. 39, 778 (1995); N. C. Karyotakis, M. C. Dignani, R. Hachem, E. J. Anaissie, ibid., p. 571; H. M. Wardle, D. Law, C. B. Moore, C. Mascn, D. W. Denning, ibid., p. 868.
22. K. V. Clemons, L. H. Hanson, D. A. Stevens, ibid., p. 1177; K. V. Clemons and D. A. Stevens, J. Med. Vet. Mycol. 32, 323 (1994); B. A. Atkinson, R. Bocanegra, A. L. Colombo, J. R. Graybill, Antimicrob. Agents Chemother. 38, 1604 (1994); K. V. Clemons and D. A. Stevens, ibid. 39, 778 (1995); N. C. Karyotakis, M. C. Dignani, R. Hachem, E. J. Anaissie, ibid., p. 571; H. M. Wardle, D. Law, C. B. Moore, C. Mascn, D. W. Denning, ibid., p. 868.
23. K. V. Clemons, L. H. Hanson, D. A. Stevens, ibid., p. 1177; K. V. Clemons and D. A. Stevens, J. Med. Vet. Mycol. 32, 323 (1994); B. A. Atkinson, R. Bocanegra, A. L. Colombo, J. R. Graybill, Antimicrob. Agents Chemother. 38, 1604 (1994); K. V. Clemons and D. A. Stevens, ibid. 39, 778 (1995); N. C. Karyotakis, M. C. Dignani, R. Hachem, E. J. Anaissie, ibid., p. 571; H. M. Wardle, D. Law, C. B. Moore, C. Mascn, D. W. Denning, ibid., p. 868.
24. A. De Maio and J. A. Urbina, Acta Cient. Venez 35, 136 (1984).
25. Neutral lipids were extracted, purified, and analyzed by capillary gas-liquid chromatography coupled to mass spectrometry as described (6, 8, 9).
26. L. J. Goad, R. L. Berens, J. J. Marr, D. H. Beach, G. G. Holz Jr., Mol. Biochem. Parasitol. 32, 179 (1989); G. Larralde, J. Vivas, J. A. Urbina, Acta Cient. Venez. 39, 140 (1988).
27. L. J. Goad, R. L. Berens, J. J. Marr, D. H. Beach, G. G. Holz Jr., Mol. Biochem. Parasitol. 32, 179 (1989); G. Larralde, J. Vivas, J. A. Urbina, Acta Cient. Venez. 39, 140 (1988).
28. Statistical analysis of the survival curves, by use of both the log rank (Mantel-Cox) and Peto-Peto-Wilcoxon tests, indicated a significant (P < 0.0001) difference between the control (untreated) animals and all those that received the drug treatments, as well as between those that received D0870 at ≥15 mg/kg per day e.o.d. and the group treated with ketoconazole at 30 mg/kg per day daily. Survival analysis was carried out on the StatView program, version 4.5, run on a Power Macintosh 7100/66 computer.
29. 125I-labeled total epimastigote surface antigen antigens with experimental sera in the presence of protein A, followed by analysis of the precipitate by SDS-polyacrylamide gel electrophoresis.
30. C. Britto, M. A. Cardoso, P. Wincker, C. M. Morel, Mem. Inst. Oswaldo Cruz Rio J. 88, 171 (1993); P. Wincker et al., Am. J. Trop. Med. Hyg. 51, 771 (1994). The T. cruzi-specific primers used in the tests were 5′-AAATAATGTACGGG(T/G)GAGATGCATGA-3′ and 5′-GGTTCGATTGGGGTTGGTGTAATATA-3′.
31. C. Britto, M. A. Cardoso, P. Wincker, C. M. Morel, Mem. Inst. Oswaldo Cruz Rio J. 88, 171 (1993); P. Wincker et al., Am. J. Trop. Med. Hyg. 51, 771 (1994). The T. cruzi-specific primers used in the tests were 5′-AAATAATGTACGGG(T/G)GAGATGCATGA-3′ and 5′-GGTTCGATTGGGGTTGGTGTAATATA-3′.
32. Statistical analysis of the survival curves, by use of both the log rank (Mantel-Cox) and Peto-Peto-Wilcoxon tests, indicated no significant differences between the control (untreated) animals and those that received ketoconazole at 30 mg/kg per day daily or D0870 at 10 mg/kg per day e.o.d., whereas there were significant differences between these groups and those receiving D0870 at 10 mg/kg per day daily (P = 0.05) or ≥15 mg/kg/day e.o.d. (P = 0.005).
33. S. De Wit, E. O'Doherty, R. P. Smith, R. Yates, N. Clumeck, Intersci. Congr. Antimicrob. Agents Chemother. Abstracts 35, F97 (1995).
34. This work was supported by the UN Development Programme-World Bank-World Health Organization Programme for Research and Training in Tropical Diseases (grant 930161) and the National Research Council of Venezuela (Consejo Nacional de Investigaciones Cientificas y Técnicas, grant RP-IV-110034). We acknowledge technical assistance by R. Lira and G. Visbal. We dedicate this paper to the memory of Jose Witremundo Torrealba.